Nasser Gholijani
1, Marjan Gharagozloo
2,3, Fathollah Kalantar
4, Amin Ramezani
5,6, Zahra Amirghofran
4,7*1 Autoimmune Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
2 Department of Immunology, Isfahan University of Medical Sciences, Isfahan, Iran.
3 Department of Pediatrics, CR-CHUS, Faculty of Medicine and Health Sciences, University of Sherbrooke, Sherbrooke,Quebec,Canada.
4 Department of Immunology, Shiraz University of Medical Sciences, Shiraz, Iran.
5 Department of Medical Biotechnology, School of Advanced Medical Sciences and Technology, Shiraz University of Medical Sciences, Shiraz, Iran.
6 Institute for Cancer Research, Shiraz University of Medical sciences, Shiraz, Iran.
7 Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract
Purpose: Thymol and carvacrol, two main
components of thyme, have
shown anti-inflammatory effects. The aim of this study was to assess the effects of these
components on Jurkat leukemia cells as an in vitro T cell model and their
molecular mechanisms of activity.
Methods: Cells were cultured in the
presence of components and subsequently stimulated with
phorbol-12-myristate-13-acetate (PMA)/calcium ionophore for evaluating
interleukin (IL)-2 and interferon (IFN)-γ production. The activation of T cell
transcription factors that included nuclear factors of activated T cells
(NFATs), activator protein-1 (AP-1; c-Jun/c-Fos), and nuclear factor (NF)-KB
were examined by Western blot analysis.
Results: Thymol and carvacrol at 25 µg/ml
significantly reduced IL-2 levels from 119.4 ± 8pg/ml in control cells treated only with
PMA/Calcium ionophore
and the solvent to
66.9 ± 6.4pg/ml (thymol) and 32.3 ± 3.6pg/ml (carvacrol) and IFN-γ from 423.7 ±
19.7pg/ml in control cells to 311.9 ± 11.6pg/ml
(thymol) and 293.5 ± 16.7pg/ml (carvacrol). Western blot analyses of nuclear extracts showed that
the same concentrations of components significantly reduced NFAT-2 to 44.2 ± 2.7% (thymol) and 91.4
± 2.3% (carvacrol) of the control (p<0.05), and c-Fos to 31.2 ± 6.2% (thymol) and 27.6 ± 3.1% (carvacrol) of
the control (p<0.01). No effects on NFAT-1, c-Jun and
phospho-NF-KBp65 levels were
observed.
Conclusion: Thymol
and carvacrol could contribute to modulation of T cell activity by reducing
IL-2 and IFN-γ production possibly through down regulation of AP-1 and NFAT-2 transcription factors suggesting their potential
usefulness for reduction of T cell overactivity in immune-mediated diseases.